Isoniazid (Laniazid, Nydrazid), also known as isonicotinylhydrazine (or INH), is an organic compound that is the first-line medication in prevention and treatment of tuberculosis. The compound was first synthesized in the early 20th century, but its activity against tuberculosis was first reported in the early 1950s, and three pharmaceutical companies attempted unsuccessfully to patent the drug simultaneously, the most prominent one being Roche, which launched its version, Rimifon, in 1952. The drug was first tested at Many Farms, a Navajo community, due to the Navajo reservation's dire tuberculosis problem and because the population was naïve with respect to streptomycin, the main tuberculosis treatment at the time. With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable.
Isoniazid is available in tablet, syrup, and injectable forms (given intramuscularly or intravenously). It is available worldwide, is inexpensive, and is generally well tolerated. It is manufactured from isonicotinic acid, which is produced from 4-methylpyridine.
The abbreviation INH is common for referring to isoniazid, but abbreviating drug names is not best practice in medicine.
- 1 Preparation
- 2 Mechanism of action
- 3 Metabolism
- 4 Dosing
- 5 Side effects
- 6 Synonyms and abbreviations
- 7 See also
- 8 References
- 9 Also see the following articles on Isoniazid
- 10 External links
- 11 List of FDA approved pharmaceutical drugs/medications sorted alphabetically
- 12 List of FDA approved drugs sorted alphabetically
Mechanism of action
Isoniazid is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme that in M. tuberculosis is called KatG. KatG couples the isonicotinic acyl with NADH to form isonicotinic acyl-NADH complex. This complex binds tightly to the enoyl-acyl carrier protein reductase known as InhA, thereby blocking the natural enoyl-AcpM substrate and the action of fatty acid synthase. This process inhibits the synthesis of mycolic acid, required for the mycobacterial cell wall. A range of radicals are produced by KatG activation of isoniazid, including nitric oxide, which has also been shown to be important in the action of another antimycobacterial prodrug PA-824.
Isoniazid reaches therapeutic concentrations in serum, cerebrospinal fluid, and within caseous granulomas. It is metabolized in the liver via acetylation. Two forms of the enzyme are responsible for acetylation, so some patients metabolize the drug more quickly than others. Hence, the half-life is bimodal, with peaks at one and three hours in the US population. The metabolites are excreted in the urine. Doses do not usually have to be adjusted in case of renal failure.
The standard dose of isoniazid in adults is 5 mg/kg/day (max 300 mg daily) for six months. The CDC and the WHO differ in their recommendation of intermittent dosing. The CDC recommends 15 mg/kg/day twice weekly (900 mg max dose), and the WHO recommends 10 mg/kg/day three times weekly (900 mg max dose) for either six or nine months. When prescribed intermittently (twice or thrice weekly), the dose is 10–15 mg/kg (max 900 mg daily), depending on the regimen chosen. Patients with slow clearance of the drug (via acetylation as described above) may require reduced dosages to avoid toxicity. The American Academy of Pediatrics recommends dosing for children of either 10–15 mg/kg/day for a daily regimen or 20–30 mg/kg/day for a twice-weekly regimen. The recommended duration of treatment is nine months in children.
Template:Refimprove section Adverse reactions include rash, abnormal liver function tests, hepatitis, sideroblastic anemia, high anion gap metabolic acidosis, peripheral neuropathy, mild central nervous system (CNS) effects, drug interactions resulting in increased phenytoin (Dilantin) or disulfiram (Antabuse) levels, intractable seizures (status epilepticus) and drug-induced lupus erythematosus.Template:Cn
Peripheral neuropathy and CNS effects are associated with the use of isoniazid and are due to pyridoxine (vitamin B6) depletion, but are uncommon at doses of 5 mg/kg.Template:Cn Persons with conditions in which neuropathy is common (e.g., diabetes, uremia, alcoholism, malnutrition, and HIV infection), as well as pregnant women and persons with a seizure disorder, may be given pyridoxine (10–50 mg/day) with isoniazid.
Isoniazid may cause severe and sometimes fatal liver damage.Template:Cn Hepatotoxicity can be avoided with close clinical monitoring of the patient, to be specific, nausea, vomiting, abdominal pain, and loss of appetite. Isoniazid is metabolized by the liver mainly by acetylation and dehydrazination. The N-acetylhydrazine metabolite is believed to be responsible for the hepatotoxic effects seen in patients treated with isoniazid. The rate of acetylation is genetically determined. About 50% of blacks and Caucasians are slow inactivators; the majority of Inuit and Asians are rapid inactivators. The half-life in fast acetylators is one to two hours, while in slow acetylators, it is two to five hours. Elimination is largely independent of renal function, but the half-life may be prolonged in liver disease. The rate of acetylation has not been shown to significantly alter the effectiveness of isoniazid. However, slow acetylation may lead to higher blood concentrations with chronic administration of the drug, with an increased risk of toxicity. Fast acetylation leads to higher blood levels of the toxic metabolite acetylisoniazid and thus to an increase in toxic reactions - hepatitis which is 250 times more common than in slow acetylators. Isoniazid and its metabolites are excreted in the urine, with 75 to 95% of the dose excreted in 24 hours. Small amounts are also excreted in saliva, sputum, and feces. Isoniazid is removed by hemodialysis and peritoneal dialysis.
Headache, poor concentration, weight gain, poor memory, insomnia, and depression have all been associated with isoniazid use.Template:Cn All patients and healthcare workers should be aware of these serious adverse effects, especially if suicidal thinking or behavior are suspected.
INH is known to reduce cytochrome P450, and in theory promotes the efficacy of contraceptives.Template:Cn Therapy is often combined with rifampin. Rifampin increases the P450 enzyme and also can reduce the efficacy of contraceptives. Alternative means of birth control should be used when taking these medications.
As previously mentioned, isoniazid is associated with pyridoxine deficiency. Pyridoxyl phosphate (derivative of pyridoxine) is required for d-aminolevulinic acid synthase, the enzyme responsible for the rate-limiting step in heme synthesis. As such, isoniazid-induced pyridoxine deficiency leads to insufficient heme formation in early red blood cells, leading to sideroblastic anemia.
Synonyms and abbreviations
- Isonicotinyl hydrazine
- Isonicotinic acid hydrazide
- H (for "hydrazide", and also the WHO standard abbreviation)
Also see the following articles on Isoniazid
- Read Wikipedia Isoniazid
Affects one in three adults
Affecting about 35 percent of all adults in the United States according to the CDC, metabolic syndrome contributes to weight gain, by causing a state of internal starvation called metabolic starvation. This in turn leads to increases hunger, sugar cravings and increased portions leading to overeating and weight gain.
Cause and effect misunderstood
Since we traditionally thought that the portion control (which in turn was attributed wrongly to poor will power)is the cause of weight gain, rather than the effect of this metabolic starvation, all our traditional ideas about cause and effect of obesity were not only wrong but lead to the “blame the victim” attitude when it comes to obesity.
Secret of weight gain revealed
Secret of weight gain, and metabolic syndrome revealed - it has been recently proven that metabolic syndrome, and the weight gain itself are caused by a process called insulin resistance. Check your metabolic syndrome risk using the free Metabolic syndrome meter. Watch this amazing Ted Med video that reveals the secret of weight loss - Stop blaming the victim for obesity
- Core Curriculum on Tuberculosis (2000) Division of Tuberculosis Elimination, Centers for Disease Control and Prevention
- See Chapter 6, Treatment of LTBI Regimens - Isoniazid::
See Chapter 7 - Treatment of TB Disease Monitoring - Adverse Reactions to First-line TB Drugs - Isoniazid::
See Table 5 First-Line Anti-TB Medications
- Isoniazid Overdose: Recognition and Management American Family Physician 1998 Feb 15
Template:Antimycobacterials Template:Cell wall disruptive antibiotics Template:Hydrazines Comprehensive list of medications or pharmaceutical drugs used in the United States with their NDC or national drug code, brand name, dosage, forms of administration etc. sorted alphabetically.
List of FDA approved pharmaceutical drugs/medications sorted alphabetically
Comprehensive list of United States Food and Drug Administration approved [[drug]s / [[medication]s sorted alphabetically.
List of FDA approved drugs sorted alphabetically
Portions of content adapted from Wikipedias article on Isoniazid licensed under GNU FDL.
<ref> tags exist, but no
<references/> tag was found